Bristol Myers Squibb’s oncology-focused campaign was developed in partnership with 2025 MM+M Agency 100 honoree Real ...
Bristol Myers Squibb remains significantly undervalued, trading at a forward P/E of 8x, versus the sector median of 19.5x. BMY's growth portfolio now generates 57% of total revenue, growing 18% YoY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results